HitGen Inc. announced that it has entered into a research agreement with Nitrase Therapeutics, Inc. (Nitrase), a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, which is a new class of enzymes discovered by Nitrase that are involved in a broad variety of diseases.
Nitrases have been implicated in numerous devastating diseases, including Parkinson
